Literature DB >> 25089863

Subclinical thyroid dysfunction and the risk for fractures: a systematic review and meta-analysis.

Christina D Wirth, Manuel R Blum, Bruno R da Costa, Christine Baumgartner, Tinh-Hai Collet, Marco Medici, Robin P Peeters, Drahomir Aujesky, Douglas C Bauer, Nicolas Rodondi.   

Abstract

BACKGROUND: Data on the association between subclinical thyroid dysfunction and fractures conflict.
PURPOSE: To assess the risk for hip and nonspine fractures associated with subclinical thyroid dysfunction among prospective cohorts. DATA SOURCES: Search of MEDLINE and EMBASE (1946 to 16 March 2014) and reference lists of retrieved articles without language restriction. STUDY SELECTION: Two physicians screened and identified prospective cohorts that measured thyroid function and followed participants to assess fracture outcomes. DATA EXTRACTION: One reviewer extracted data using a standardized protocol, and another verified data. Both reviewers independently assessed methodological quality of the studies. DATA SYNTHESIS: The 7 population-based cohorts of heterogeneous quality included 50,245 participants with 1966 hip and 3281 nonspine fractures. In random-effects models that included the 5 higher-quality studies, the pooled adjusted hazard ratios (HRs) of participants with subclinical hyperthyroidism versus euthyrodism were 1.38 (95% CI, 0.92 to 2.07) for hip fractures and 1.20 (CI, 0.83 to 1.72) for nonspine fractures without statistical heterogeneity (P = 0.82 and 0.52, respectively; I2= 0%). Pooled estimates for the 7 cohorts were 1.26 (CI, 0.96 to 1.65) for hip fractures and 1.16 (CI, 0.95 to 1.42) for nonspine fractures. When thyroxine recipients were excluded, the HRs for participants with subclinical hyperthyroidism were 2.16 (CI, 0.87 to 5.37) for hip fractures and 1.43 (CI, 0.73 to 2.78) for nonspine fractures. For participants with subclinical hypothyroidism, HRs from higher-quality studies were 1.12 (CI, 0.83 to 1.51) for hip fractures and 1.04 (CI, 0.76 to 1.42) for nonspine fractures (P for heterogeneity = 0.69 and 0.88, respectively; I2 = 0%). LIMITATIONS: Selective reporting cannot be excluded. Adjustment for potential common confounders varied and was not adequately done across all studies.
CONCLUSION: Subclinical hyperthyroidism might be associated with an increased risk for hip and nonspine fractures, but additional large, high-quality studies are needed. PRIMARY FUNDING SOURCE: Swiss National Science Foundation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25089863      PMCID: PMC4403766          DOI: 10.7326/M14-0125

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  61 in total

Review 1.  Thyroid hormone metabolism in skeletal development and adult bone maintenance.

Authors:  Julian A Waung; J H Duncan Bassett; Graham R Williams
Journal:  Trends Endocrinol Metab       Date:  2011-12-12       Impact factor: 12.015

2.  Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism.

Authors:  G Das; T A Ojewuyi; P Baglioni; J Geen; L D Premawardhana; O E Okosieme
Journal:  Clin Endocrinol (Oxf)       Date:  2012-07       Impact factor: 3.478

3.  Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysis.

Authors:  Nicolas Rodondi; Drahomir Aujesky; Eric Vittinghoff; Jacques Cornuz; Douglas C Bauer
Journal:  Am J Med       Date:  2006-07       Impact factor: 4.965

4.  Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head.

Authors:  Jesse A Berlin; Jill Santanna; Christopher H Schmid; Lynda A Szczech; Harold I Feldman
Journal:  Stat Med       Date:  2002-02-15       Impact factor: 2.373

Review 5.  Meta-Analysis. Potentials and promise.

Authors:  M Egger; G D Smith
Journal:  BMJ       Date:  1997-11-22

6.  Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women.

Authors:  J Faber; I W Jensen; L Petersen; B Nygaard; L Hegedüs; K Siersbaek-Nielsen
Journal:  Clin Endocrinol (Oxf)       Date:  1998-03       Impact factor: 3.478

7.  Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis.

Authors:  J Faber; A M Galløe
Journal:  Eur J Endocrinol       Date:  1994-04       Impact factor: 6.664

8.  Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial.

Authors:  Christian Meier; Müller Beat; Merih Guglielmetti; Mirjam Christ-Crain; Jean-Jacques Staub; Marius Kraenzlin
Journal:  Osteoporos Int       Date:  2004-01-16       Impact factor: 4.507

9.  International variations in hip fracture probabilities: implications for risk assessment.

Authors:  John A Kanis; Olof Johnell; Chris De Laet; Bengt Jonsson; Anders Oden; Alan K Ogelsby
Journal:  J Bone Miner Res       Date:  2002-07       Impact factor: 6.741

10.  Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality.

Authors:  Nicolas Ochs; Reto Auer; Douglas C Bauer; David Nanchen; Jacobijn Gussekloo; Jacques Cornuz; Nicolas Rodondi
Journal:  Ann Intern Med       Date:  2008-05-19       Impact factor: 25.391

View more
  23 in total

1.  Thyroid Hormone Therapy and Risk of Thyrotoxicosis in Community-Resident Older Adults: Findings from the Baltimore Longitudinal Study of Aging.

Authors:  Jennifer S Mammen; John McGready; Rachael Oxman; Chee W Chia; Paul W Ladenson; Eleanor M Simonsick
Journal:  Thyroid       Date:  2015-08-13       Impact factor: 6.568

Review 2.  The association between serum uric acid level and the risk of fractures: a systematic review and meta-analysis.

Authors:  P Yin; H Lv; Y Li; Y Meng; L Zhang; P Tang
Journal:  Osteoporos Int       Date:  2017-05-09       Impact factor: 4.507

3.  Association of subclinical thyroid dysfunction with bone mineral density and fracture: a meta-analysis of prospective cohort studies.

Authors:  Hongling Zhu; Jichen Zhang; Jingnan Wang; Xuemei Zhao; Mingjun Gu
Journal:  Endocrine       Date:  2019-11-13       Impact factor: 3.633

Review 4.  Type 1 diabetes and risk of fracture: meta-analysis and review of the literature.

Authors:  V N Shah; C S Shah; J K Snell-Bergeon
Journal:  Diabet Med       Date:  2015-06-12       Impact factor: 4.359

5.  Relationship between subclinical thyroid dysfunction and the risk of fracture: a meta-analysis of prospective cohort studies.

Authors:  Z Yan; H Huang; J Li; J Wang
Journal:  Osteoporos Int       Date:  2015-07-30       Impact factor: 4.507

Review 6.  Skeletal health in patients with differentiated thyroid carcinoma.

Authors:  M Cellini; M Rotondi; M L Tanda; E Piantanida; L Chiovato; P Beck-Peccoz; Andrea Lania; G Mazziotti
Journal:  J Endocrinol Invest       Date:  2020-07-21       Impact factor: 4.256

Review 7.  Bariatric Surgery: Bad to the Bone, Part 2.

Authors:  Lara Pizzorno
Journal:  Integr Med (Encinitas)       Date:  2016-04

Review 8.  Subclinical Thyroid Dysfunction and the Risk of Cognitive Decline: a Meta-Analysis of Prospective Cohort Studies.

Authors:  Carole Rieben; Daniel Segna; Bruno R da Costa; Tinh-Hai Collet; Layal Chaker; Carole E Aubert; Christine Baumgartner; Osvaldo P Almeida; Eef Hogervorst; Stella Trompet; Kamal Masaki; Simon P Mooijaart; Jacobijn Gussekloo; Robin P Peeters; Douglas C Bauer; Drahomir Aujesky; Nicolas Rodondi
Journal:  J Clin Endocrinol Metab       Date:  2016-09-30       Impact factor: 5.958

9.  The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism.

Authors:  Bernadette Biondi; Luigi Bartalena; David S Cooper; Laszlo Hegedüs; Peter Laurberg; George J Kahaly
Journal:  Eur Thyroid J       Date:  2015-08-26

10.  2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.

Authors:  George J Kahaly; Luigi Bartalena; Lazlo Hegedüs; Laurence Leenhardt; Kris Poppe; Simon H Pearce
Journal:  Eur Thyroid J       Date:  2018-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.